|
|
-
2011 IAS Conference on HIV Pathogenesis, Treatment and Prevention
July 17-20, 2011
| Rome, Italy
CCO's official conference coverage of the 2011 IAS Conference on HIV Pathogenesis, Treatment and Prevention includes capsule summaries, expert faculty analysis of clinically relevant data presented at the meeting, audio podcasts and a downloadable slideset that focuses on key issues highlighted at the conference.
-
Beatriz Grinsztejn, MD, PhD, and Jean Nachega, MD, PhD, discuss the challenges and forward momentum of HIV treatment in resource-limited settings, particularly sub-Saharan Africa.
-
Review data from this important international meeting with expert faculty Anton L. Pozniak, MD, FRCP; Ian M. Sanne, MBBCH, FCP(SA); and Kimberly Y. Smith, MD, MPH, and see how they would apply this information to care of their HIV-infected patients.
-
In this downloadable slideset, Eric S. Daar, MD, and Joel E. Gallant, MD, MPH, review key studies from the 2011 International AIDS Society conference.
Latest Content
-
Beatriz Grinsztejn, MD, PhD, and Jean Nachega, MD, PhD, discuss the challenges and forward momentum of HIV treatment in resource-limited settings, particularly sub-Saharan Africa.
Faculty: Beatriz Grinsztejn MD, PhD, Jean B. Nachega MD, PhD
Released: 9/15/2011
-
Review data from this important international meeting with expert faculty Anton L. Pozniak, MD, FRCP; Ian M. Sanne, MBBCH, FCP(SA); and Kimberly Y. Smith, MD, MPH, and see how they would apply this information to care of their HIV-infected patients.
Faculty: Anton L. Pozniak MD, FRCP, Ian M. Sanne MBBCH, FCP(SA), Kimberly Y. Smith MD, MPH
Released: 9/15/2011
-
In this downloadable slideset, Eric S. Daar, MD, and Joel E. Gallant, MD, MPH, review key studies from the 2011 International AIDS Society conference.
Date Posted: 8/3/2011
-
36 weeks following antiretroviral therapy interruption, HIV-1 RNA remained 0.44 log10 copies/mL lower in 48-week antiretroviral therapy vs SOC arm.
Date Posted: 7/22/2011
-
Concomitant use of PI with tenofovir for ≥ 6 months associated with 3.5-fold increase in relative risk of chronic kidney disease.
Date Posted: 7/22/2011
-
As seen with other integrase inhibitors, early rapid virologic decay did not translate into superior long-term efficacy.
Date Posted: 7/21/2011
-
Although early antiretroviral therapy more than doubled the risk of TB-IRIS, it was manageable with only 3.9% mortality.
Date Posted: 7/21/2011
-
Highest incidence of TB-IRIS with early integrated antiretroviral therapy seen in patients with CD4+ counts < 50 cells/mm³: 45.5 cases/100 patient-years.
Date Posted: 7/21/2011
-
In addition to near elimination of genetically confirmed HIV transmissions within couples, a 41% reduction in HIV-related clinical events was observed among HIV-infected individuals randomized to immediate vs delayed therapy.
Date Posted: 7/20/2011
-
Daily oral PrEP taken by HIV-negative partners in HIV-serodiscordant heterosexual couples significantly reduced risk of HIV transmission by 62% with tenofovir alone and by 73% with tenofovir/emtricitabine; effect similar in men and women.
Date Posted: 7/20/2011
Conference News – Reported by NAM
|
|
|
|
|
Click here for more news reports and to learn more about NAM. |
|
Partnership Information
|
|
|
IAS 2011 conference organizers are using a blog and other social media to communicate with delegates attending the meeting and with those following the conference from home.
IAS 2011 Blog
Read the IAS 2011 blog for posts from conference organizers and guest bloggers.
Social Media
IAS 2011 updates are available at Facebook, Twitter, YouTube, and SmugMug.
For more information about these resources and IAS 2011, go to www.ias2011.org.
|
|
www.aidsmap.com provides comprehensive news coverage of IAS 2011, with news reports each day and a daily summary email bulletin for those who want just the highlights of the meeting.
To view the daily news coverage, and to sign up for the daily highlights bulletin (also available in French, Spanish, Portuguese and Russian) go to www.aidsmap.com/ias2011. |
|
|
Jointly sponsored/co-provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|